Ocugen Inc to Discuss Updated Results from the Phase 1/2 Trial of OCU400 Investor Call Transcript
Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ocugen, Inc., business update conference call. (Operator instructions)
Tiffany Hamilton, Head of Communications, you may begin your conference.
Thank you. Good morning. Early this morning, we issued a press release announcing a positive clinical study update for safety and efficacy results from our Phase 1/2 trial of OCU400, a modifier gene therapy product for the treatment of retinitis pigmentosa and Leber congenital amaurosis. We encourage listeners to review the press release, which is available on our website at ocugen.com.
This call is being recorded, and a replay of the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |